Drugs / HDM2024
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07539285 | Apr 2026 → Apr 2027 expected | cancer | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HDM2024 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07539285 ↗ |
| Target | EGFR | “ADC drug targeting EGFR and HER3” NCT07539285 ↗ |